Research

Osmanska, J., Petrie, M. C., Docherty, K. F., Lee, M. M.Y., McMurray, J. J.V., Campbell, R. (2024) Subcutaneous furosemide in heart failure: a systematic review. European Heart Journal: Cardiovascular Pharmacotherapy, (doi: 10.1093/ehjcvp/pvae083)

Docherty, K. F., Buendia Lopez, R., Folkvaljon, F., de Boer, R. A., Chen, J., Hammarstedt, A., Kitzman, D. W., Kosiborod, M. N., Langkilde, A. M., Reicher, B., Senni, M., Wilderäng, U., Verma, S., Cowie, M. R., Solomon, S. D., McMurray, J. (2024) Wearable accelerometer-derived measures of physical activity in heart failure: insights from the DETERMINE trials. Journal of Cardiac Failure,

Lee, M., Petrie, M. C., Cleland, J. G.F., Donnelly, P., Francis, M., Hannah, A., Japp, A. G., Labinjoh, C., Lang, N. N., Mainsty, C., Petrie, C. J., Piper, S. E., Williams, S. G., Ford, I., Kalra, P. R., IRONMAN Trial Investigators, (2024) Administration of ferric derisomaltose for iron deficiency and heart failure during hospital admission or at the clinic – insights from the IRONMAN trial. European Journal of Heart Failure, 26, pp. 2293-2295. (doi: 10.1002/ejhf.3394)

Docherty, K. F., Lopez, R. B., Folkvaljon, F., de Boer, R. A., Cowie, M. R., Hammarstedt, A., Kitzman, D. W., Kosiborod, M. N., Langkilde, A. M., Reicher, B., Senni, M., Shah, S. J., Verma, S., Solomon, S. D., McMurray, J. J.V. (2024) Effect of dapagliflozin on accelerometer-based measures of physical activity in patients with heart failure: an analysis of the DETERMINE trials. Circulation: Heart Failure, 17, (doi: 10.1161/CIRCHEARTFAILURE.124.012349)

Lee, M., Aimo, A., Bayés-Genís, A. (2024) Reverse cardiac remodelling: VICTORIA for inflammation and cardiac metabolism. European Journal of Heart Failure, 26, pp. 2240-2242. (doi: 10.1002/ejhf.3421)

Lee, M. M.Y., Codina, P., Tomasoni, D., Aimo, A. (2024) What’s new in heart failure? October 2024. European Journal of Heart Failure, 26, pp. 2049-2054. (doi: 10.1002/ejhf.3492)

Doherty, D. J., Abdin, A., Docherty, K. F. (2024) Heart failure medical therapy in the last years of life: prognosis and practicalities. European Journal of Heart Failure, (doi: 10.1002/ejhf.3450)

Coats, C. J. et al. (2024) Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial. European Heart Journal, (doi: 10.1093/eurheartj/ehae590)

Butt, J., Jhund, P. S., Docherty, K. F., Claggett, B. L., Vaduganathan, M., Bachus, E., Hernandez, A. F., Lam, C. S.P., Inzucchi, S. E., Martinez, F. A., de Boer, R. A., Kosiborod, M. N., Desai, A. S., Køber, L., Ponikowski, P., Sabatine, M. S., Solomon, S. D., McMurray, J. J.V. (2024) Dapagliflozin and timing of prior heart failure hospitalization a patient-level meta-analysis of DAPA-HF and DELIVER. JACC: Heart Failure, 12, pp. 1586-1599. (doi: 10.1016/j.jchf.2024.01.018)

Ryan, M., Taylor, D., Dodd, M., Spertus, J. A., Kosiborod, M. N., Shaukat, A., Docherty, K. F., Clayton, T., Perera, D., Petrie, M. C., REVIVED-BCIS2 Investigators, (2024) Effect of PCI on health status in ischemic left ventricular dysfunction: insights from REVIVED-BCIS2. JACC: Heart Failure, 12, pp. 1553-1562. (doi: 10.1016/j.jchf.2024.03.010)

Cameron, A., Arnold, M., Katsas, G., Yang, J., Quinn, T. J., Abdul-Rahim, A. H., Campbell, R., Docherty, K., De Marchis, G. M., Arnold, M., Kahles, T., Nedeltchev, K., Cereda, C., Kaegi, G., Bustamante, A., Montaner, J., Ntaios, G., Foerch, C., Spanaus, K., Von Eckardstein, A., Dawson, J., Katan, M. (2024) Natriuretic peptides to classify risk of atrial fibrillation detection after stroke: analysis of the BIOSIGNAL and PRECISE cohort studies. Neurology, 103, (doi: 10.1212/WNL.0000000000209625)

Coats, C. J. et al. (2024) Dosing and safety profile of aficamten in symptomatic obstructive hypertrophic cardiomyopathy: results from from SEQUOIA‐HCM. Journal of the American Heart Association, 13, (doi: 10.1161/JAHA.124.035993)

Carberry, J., Petrie, M. C., Lee, M. M.Y., Brooksbank, K., Campbell, R. T., Good, R., Jhund, P. S., Kellman, P., Lang, N. N., Mangion, K., Mark, P. B., McConnachie, A., McMurray, J. J.V., Meyer, B., Orchard, V., Shaukat, A., Watkins, S., Welsh, P., Sattar, N., Berry, C., Docherty, K. F. (2024) Empagliflozin to prevent progressive adverse remodelling after myocardial infarction (EMPRESS-MI): rationale and design. ESC Heart Failure, 11, pp. 2001-2012. (doi: 10.1002/ehf2.14830)

Docherty, K. F., McMurray, J. J.V., Kalra, P., Cleland, J. G.F., Lang, N. N., Petrie, M. C., Robertson, M., Ford, I. (2024) Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction. ESC Heart Failure, 11, pp. 1875-1879. (doi: 10.1002/ehf2.14742)

Espersen, C., Campbell, R. T., Claggett, B. L., Lewis, E. F., Docherty, K. F., Lee, M. M.Y., Lindner, M., Brainin, P., Biering-Sørensen, T., Solomon, S. D., McMurray, J. J.V., Platz, E. (2024) Predictors of heart failure readmission and all-cause mortality in patients with acute heart failure. International Journal of Cardiology, 406, (doi: 10.1016/j.ijcard.2024.132036)

Carberry, J., Marquis-Gravel, G., O’Meara, E., Docherty, K. F. (2024) Where are we with treatment and prevention of heart failure in patients post myocardial infarction? JACC: Heart Failure, 12, pp. 1157-1165. (doi: 10.1016/j.jchf.2024.04.025)

Yang, M., Kondo, T., Talebi, A., Jhund, P. S., Docherty, K. F., Claggett, B. L., Vaduganathan, M., Bachus, E., Hernandez, A. F., Lam, C. S.P., Inzucchi, S. E., Martinez, F. A., de Boer, R. A., Kosiborod, M. N., Desai, A. S., Køber, L., Ponikowski, P., Sabatine, M. S., Solomon, S. D., McMurray, J. J.V. (2024) Dapagliflozin and quality of life measured using the EuroQol 5-Dimension questionnaire in patients with HFrEF and HFmrEF/HFpEF. European Journal of Heart Failure, 26, pp. 1524-1538. (doi: 10.1002/ejhf.3263)

Shen, L., Lee, M. M.Y., Jhund, P. S., Granger, C. B., Anand, I. S., Maggioni, A. P., Pfeffer, M. A., Solomon, S. D., Swedberg, K., Yusuf, S., McMurray, J. J.V. (2024) Revisiting race and the benefit of RAS blockade in heart failure. A meta-analysis of randomized clinical trials. JAMA: Journal of the American Medical Association, 331, (doi: 10.1001/jama.2024.6774)

Traub, J., Docherty, K. F., Frey, A. (2024) The link between heart failure and neurodegeneration insights from circulating biomarkers. JACC: Heart Failure, 12, pp. 1086-1088. (doi: 10.1016/j.jchf.2024.04.008)

Curtain, J. P., Talebi, A., McIntosh, A., McConnachie, A., O’Donnell, J., Welsh, P., Osmanska, J., Lee, M. M.Y., Sonecki, P., Akl, T., Seo, J., Gopinathan, V., Hurwitz, J., Thiagarajan, S., Pettit, S., Kalra, P. R., Patel, R. K., Mark, P. B., Lang, N. N., McMurray, J. J.V., Petrie, M. C., Gardner, R. S., Jhund, P. S. (2024) Measuring congestion with a non-invasive monitoring device in heart failure and haemodialysis: CONGEST-HF. European Journal of Heart Failure, 26, pp. 1383-1392. (doi: 10.1002/ejhf.3290)

Sattar, N., Lee, M. M.Y., McGuire, D. K. (2024) What the SELECT trial of semaglutide means for clinicians. Nature Medicine, 30, pp. 1830-1831. (doi: 10.1038/s41591-024-03013-7)

Kondo, T., Mogensen, U. M., Talebi, A., Gasparyan, S. B., Campbell, R. T., Docherty, K. F., de Boer, R. A., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Sabatine, M. S., Bengtsson, O., Sjöstrand, M., Vaduganathan, M., Solomon, S. D., Jhund, P. S., McMurray, J. J.V. (2024) Dapagliflozin and days of full health lost through death, hospitalization, and impaired well-being in DAPA-HF. Journal of the American College of Cardiology, 83, pp. 1973-1986. (doi: 10.1016/j.jacc.2024.03.385)

Lassen, M. C. H., Ostrominski, J. W., Inzucchi, S. E., Claggett, B. L., Kulac, I., Jhund, P., de Boer, R. A., Hernandez, A. F., Kosiborod, M. N., Lam, C. S.P., Martinez, F. A., Shah, S. J., Desai, A. S., Petersson, M., Langkilde, A. M., Docherty, K. F., McMurray, J. J.V., Solomon, S. D., Vaduganathan, M. (2024) Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: a pre‐specified analysis of the DELIVER trial. European Journal of Heart Failure, 26, pp. 1539-1548. (doi: 10.1002/ejhf.3269)

Maron, M. S. et al. (2024) Aficamten for symptomatic obstructive hypertrophic cardiomyopathy. New England Journal of Medicine, 390, pp. 1849-1861. (doi: 10.1056/nejmoa2401424)

McDowell, K., Kondo, T., Talebi, A., Teh, K., Bachus, E., de Boer, R. A., Campbell, R. T., Claggett, B., Desai, A. S., Docherty, K. F., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S.P., Martinez, F., Simpson, J., Vaduganathan, M., Jhund, P. S., Solomon, S. D., McMurray, J. J.V. (2024) Prognostic models for mortality and morbidity in heart failure with preserved ejection fraction. JAMA Cardiology, 9, (doi: 10.1001/jamacardio.2024.0284)

Buendia, R., Karpefors, M., Folkvaljon, F., Hunter, R., Sillen, H., Luu, L., Docherty, K., Cowie, M. R. (2024) Wearable sensors to monitor physical activity in heart failure clinical trials: state-of-the-art review. Journal of Cardiac Failure, 30, pp. 703-716. (doi: 10.1016/j.cardfail.2024.01.016)

Sattar, N., Butler, J., Lee, M. M.Y., Harrington, J., Sharma, A., Zannad, F., Filippatos, G., Verma, S., Januzzi, J. L., Ferreira, J. P., Pocock, S. J., Pfarr, E., Ofstad, A. P., Brueckmann, M., Packer, M., Anker, S. D. (2024) Body mass index and cardiorenal outcomes in the EMPEROR-Preserved trial: principal findings and meta-analysis with the DELIVER trial. European Journal of Heart Failure, 26, pp. 900-909. (doi: 10.1002/ejhf.3221)

Campbell, P., Rutten, F. H., Lee, M. M. Y., Hawkins, N. M., Petrie, M. C. (2024) Heart failure with preserved ejection fraction: Everything the clinician needs to know. Lancet, 403, pp. 1083-1092. (doi: 10.1016/S0140-6736(23)02756-3)

Goldie, F. C., Lee, M. M. Y., Coats, C. J., Nordin, S. (2024) Advances in multi-modality imaging in hypertrophic cardiomyopathy. Journal of Clinical Medicine, 13, (doi: 10.3390/jcm13030842)

Lee, M. M.Y., Masri, A. (2024) Correction to: Differentiating cardiac troponin levels during cardiac myosin inhibition or cardiac myosin activation treatments: drug effect or the canary in the coal mine? Current Heart Failure Reports, 21, pp. 61. (doi: 10.1007/s11897-023-00639-5)

Brum, W. S., Docherty, K. F., Ashton, N. J., Zetterberg, H., Hansson, O., McMurray, J. J. V., Blennow, K. (2024) Effect of neprilysin inhibition on Alzheimer disease plasma biomarkers: a secondary analysis of a randomized clinical trial. JAMA Neurology, 81, pp. 197-200. (doi: 10.1001/jamaneurol.2023.4719)

Osmanska, J., Brooksbank, K., Docherty, K. F., Robertson, S., Wetherall, K., McConnachie, A., Hu, J., Gardner, R. S., Clark, A. L., Squire, I. B., Kalra, P. R., Jhund, P. S., Muntendam, P., McMurray, J. J.V., Petrie, M. C., Campbell, R. T. (2024) A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies. European Heart Journal: Cardiovascular Pharmacotherapy, 10, pp. 35-44. (doi: 10.1093/ehjcvp/pvad073)

Lee, M. M.Y., Kondo, T., Campbell, R. T., Petrie, M. C., Sattar, N., Solomon, S. D., Vaduganathan, M., Jhund, P. S., McMurray, J. J.V. (2024) Effects of Renin-Angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomised controlled trials. European Heart Journal: Cardiovascular Pharmacotherapy, 10, pp. 68-80. (doi: 10.1093/ehjcvp/pvad067)

Coats, C. J. et al. (2024) Exercise capacity in patients with obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM baseline characteristics and study design. JACC: Heart Failure, 12, pp. 199-215. (doi: 10.1016/j.jchf.2023.10.004)

Docherty, K. F., McMurray, J. J.V., Diaz, R., Felker, G. M., Metra, M., Solomon, S. D., Adams, K. F., Böhm, M., Brinkley, D. M., Echeverria, L. E., Goudev, A. R., Howlett, J. G., Lund, M., Ponikowski, P., Yilmaz, M. B., Zannad, F., Claggett, B. L., Miao, Z. M., Abbasi, S. A., Divanji, P., Heitner, S. B., Kupfer, S., Malik, F. I., Teerlink, J. R. (2024) The effect of omecamtiv mecarbil in hospitalized patients as compared with outpatients with HFrEF: an analysis of GALACTIC-HF. Journal of Cardiac Failure, 30, pp. 26-35. (doi: 10.1016/j.cardfail.2023.08.020)

Lee, M. M.Y., Lean, M. E.J., Sattar, N., Petrie, M. C. (2023) Appetite and its regulation: Are there palatable interventions for heart failure? Current Heart Failure Reports, 21, pp. 1-4. (doi: 10.1007/s11897-023-00637-7)

McMurray, J. J.V., Docherty, K. F., de Boer, R. A., Hammarstedt, A., Kitzman, D. W., Kosiborod, M. N., Langkilde, A. M., Reicher, B., Senni, M., Shah, S. J., Wilderäng, U., Verma, S., Solomon, S. D. (2023) Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials. Circulation, (doi: 10.1161/CIRCULATIONAHA.123.065061)

Connelly, P., Osmanska, J., Lee, M. M.Y., Delles, C., McEntegart, M. B., Byrne, J. (2023) A case report of myocardial infarction in a young transgender man with testosterone therapy? raising awareness on healthcare issues in the transgender community and a call for further research. European Heart Journal: Case Reports, 7, (doi: 10.1093/ehjcr/ytad562)

Matsumoto, S., Kondo, T., Yang, M., Campbell, R. T., Docherty, K. F., de Boer, R. A., Desai, A. S., Lam, C. S.P., Packer, M., Pitt, B., Rouleau, J. L., Vaduganathan, M., Zannad, F., Zile, M. R., Solomon, S. D., Jhund, P. S., McMurray, J. J.V. (2023) Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. European Journal of Heart Failure, 25, pp. 2202-2214. (doi: 10.1002/ejhf.3044)

Lee, M. M. Y., Masri, A. (2023) Differentiating cardiac troponin levels during cardiac myosin inhibition or cardiac myosin activation treatments: drug effect or the canary in the coal mine? Current Heart Failure Reports, 20, pp. 504-518. (doi: 10.1007/s11897-023-00620-2)

Kondo, T., Butt, J. H., Curtain, J. P., Jhund, P. S., Docherty, K. F., Claggett, B. L., Vaduganathan, M., Bachus, E., Hernandez, A. F., Lam, C. S.P., Inzucchi, S. E., Martinez, F. A., de Boer, R. A., Kosiborod, M. N., Desai, A. S., Køber, L., Ponikowski, P., Sabatine, M. S., Solomon, S. D., McMurray, J. J.V. (2023) Efficacy of dapagliflozin according to heart rate: A patient-level pooled analysis of DAPA-HF and DELIVER. Circulation: Heart Failure, 16, (doi: 10.1161/CIRCHEARTFAILURE.123.010898)

Chatur, S., Vaduganathan, M., Claggett, B. L., Cunningham, J. W., Docherty, K. F., Desai, A. S., Jhund, P. S., De Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F. A., Shah, S. J., Petersson, M., Langkilde, A.-M., McMurray, J. J. V., Solomon, S. D. (2023) Outpatient worsening among patients with mildly reduced and preserved ejection fraction heart failure in the DELIVER trial. Circulation, 148, pp. 1735-1745. (doi: 10.1161/circulationaha.123.066506)

Mc Causland, F. R., Claggett, B. L., Vaduganathan, M., Desai, A., Jhund, P., Vardeny, O., Fang, J. C., de Boer, R. A., Docherty, K. F., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Saraiva, J. F. K., McGrath, M. M., Shah, S. J., Verma, S., Langkilde, A. M., Petersson, M., McMurray, J. J. V., Solomon, S. D. (2023) Decline in estimated glomerular filtration rate after dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: A prespecified secondary analysis of the DELIVER randomized clinical trial. JAMA Cardiology, 9, pp. 144-152. (doi: 10.1001/jamacardio.2023.4664)

Heerspink, H. J. L., Vart, P., Jongs, N., Neuen, B. L., Bakris, G., Claggett, B., Vaduganathan, M., McCausland, F., Docherty, K. F., Jhund, P. S.,, Solomon, S. D., Perkovic, V., McMurray, J. J. V. (2023) Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: a joint analysis of randomized controlled clinical trials. Diabetes, Obesity and Metabolism, 25, pp. 3327-3336. (doi: 10.1111/dom.15232)

Docherty, K. F. (2023) SGLT2 inhibitors and iron: more than meets the eye. JACC: Heart Failure, 11, pp. 1623-1625. (doi: 10.1016/j.jchf.2023.08.013)

Butt, J., Docherty, K. F., Kosiborod, M. N., Inzucchi, S. E., Køber, L., Langkilde, A. M., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., Sjöstrand, M., Solomon, S., Jhund, P. S., McMurray, J. J.V. (2023) Dapagliflozin and physical and social activity limitations in heart failure with reduced ejection fraction. JACC: Heart Failure, 11, pp. 1411-1423. (doi: 10.1016/j.jchf.2023.04.016)

Lam, C. S.P., Docherty, K. F., Ho, J. E., McMurray, J. J.V., Myhre, P. L., Omland, T. (2023) Recent successes in heart failure treatment. Nature Medicine, 29, pp. 2424-2437. (doi: 10.1038/s41591-023-02567-2)

Brennan, A. C., Campbell, R. T., Lee, M. M.Y. (2023) Influenza vaccination: a simple, safe, and effective treatment for patients with ischaemic heart disease and heart failure. European Journal of Heart Failure, 25, pp. 1693-1695. (doi: 10.1002/ejhf.2993)

Yeoh, S. E., Osmanska, J., Petrie, M. C., Brooksbank, K. J.M., Clark, A. L., Docherty, K. F., Foley, P. W.X., Guha, K., Halliday, C. A., Jhund, P. S., Kalra, P. R., McKinley, G., Lang, N. N., Lee, M. M.Y., McConnachie, A., McDermott, J. J., Platz, E., Sartipy, P., Seed, A., Stanley, B., Weir, R. A.P., Welsh, P., McMurray, J. J.V., Campbell, R. T. (2023) Dapagliflozin versus metolazone in heart failure resistant to loop diuretics. European Heart Journal, 44, pp. 2966-2977. (doi: 10.1093/eurheartj/ehad341)

Docherty, K. F., Jackson, A. M., Macartney, M., Campbell, R. T., Petrie, M. C., Pfeffer, M. A., McMurray, J. J.V., Jhund, P. S. (2023) Declining risk of heart failure hospitalization following first acute myocardial infarction in Scotland between 1991–2016. European Journal of Heart Failure, 25, pp. 1213-1224. (doi: 10.1002/ejhf.2965)

Chatur, S., Kondo, T., Claggett, B. L., Docherty, K., Miao, Z. M., Desai, A. S., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F. A., Shah, S. J., Petersson, M., Langkilde, A. M., McMurray, J. J.V., Solomon, S. D., Vaduganathan, M. (2023) Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: insights from DELIVER and DAPA-HF. European Journal of Heart Failure, 25, pp. 1364-1371. (doi: 10.1002/ejhf.2912)

Docherty, K. F., Lam, C. S.P., Rakisheva, A., Coats, A. J.S., Greenhalgh, T., Metra, M., Petrie, M. C., Rosano, G. M.C. (2023) Heart failure diagnosis in the general community - who, how and when? A clinical consensus statement of the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure, 25, pp. 1185-1198. (doi: 10.1002/ejhf.2946)

Docherty, K. F., McDowell, K., Welsh, P., Osmanska, J., Anand, I., de Boer, R. A., Køber, L., Kosiborod, M. N., Martinez, F. A., O’Meara, E., Ponikowski, P., Schou, M., Berg, D. D., Sabatine, M. S., Morrow, D. A., Jarolim, P., Hammarstedt, A., Sjöstrand, M., Langkilde, A. M., Solomon, S. D., Sattar, N., Jhund, P. S., McMurray, J. J.V. (2023) Association of carbohydrate antigen 125 on the response to dapagliflozin in patients with heart failure. Journal of the American College of Cardiology, 82, pp. 142-157. (doi: 10.1016/j.jacc.2023.05.011)

Lee, M. M.Y., Sattar, N. (2023) A review of current key guidelines for managing high risk patients with diabetes and heart failure and future prospects. Diabetes, Obesity and Metabolism, 25, pp. 33-47. (doi: 10.1111/dom.15085)

Talha, K. M., Butler, J., Greene, S. J., Aggarwal, R., Anker, S. D., Claggett, B. L., Docherty, K. F., Solomon, S. D., McMurray, J. J.V., Januzzi, J. L., Vaduganathan, M., Fonarow, G. C. (2023) Potential global impact of sodium‐glucose cotransporter‐2 inhibitors in heart failure. European Journal of Heart Failure, 25, pp. 999-1009. (doi: 10.1002/ejhf.2864)

Curtain, J. P., Adamson, C., Docherty, K. F., Jhund, P. S., Desai, A. S., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Swedberg, K., Zile, M. R., Solomon, S. D., Packer, M., McMurray, J. J.V. (2023) Prevalent and incident anemia in PARADIGM-HF and the effect of sacubitril/valsartan. JACC: Heart Failure, 11, pp. 749-759. (doi: 10.1016/j.jchf.2022.12.012)

Butt, J. H., Kondo, T., Yang, M., Jhund, P. S., Docherty, K. F., Vaduganathan, M., Claggett, B. L., Hernandez, A. F., Lam, C. S.P., Inzucchi, S. E., Martinez, F. A., de Boer, R. A., Kosiborod, M. N., Desai, A. S., Køber, L., Ponikowski, P., Sabatine, M. S., Shah, S. J., Zaozerska, N., Wilderäng, U., Bengtsson, O., Solomon, S. D., McMurray, J. J.V. (2023) Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. European Heart Journal, 44, pp. 2170-2183. (doi: 10.1093/eurheartj/ehad276)

Campbell, R. T., Docherty, K. F. (2023) Serum bicarbonate and congestion: a potential biomarker for identifying and guiding management in diuretic resistance? European Heart Journal, 44, pp. 2006-2008. (doi: 10.1093/eurheartj/ehad209)

Curtain, J. P., Lee, M. M.Y., McMurray, J. J.V., Gardner, R. S., Petrie, M. C., Jhund, P. S. (2023) Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis. Heart, 109, pp. 823-831. (doi: 10.1136/heartjnl-2022-321885)

Yeoh, S. E., Docherty, K. F., Campbell, R. T., Jhund, P. S., Hammarstedt, A., Heerspink, H. J.L., Jarolim, P., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Solomon, S. D., Sjöstrand, M., Bengtsson, O., Greasley, P. J., Sattar, N., Welsh, P., Sabatine, M. S., Morrow, D. A., McMurray, J. J.V. (2023) Endothelin-1, outcomes in patients with heart failure and reduced ejection fraction, and effects of dapagliflozin: findings from DAPA-HF. Circulation, 147, pp. 1670-1683. (doi: 10.1161/CIRCULATIONAHA.122.063327)

Lee, M. M. Y., McMurray, J. J. V. (2023) Lack of benefit of renin-angiotensin system inhibitors in COVID-19. JAMA: Journal of the American Medical Association, 329, pp. 1155-1156. (doi: 10.1001/jama.2023.4405)

Butt, J. H., Docherty, K. F., Claggett, B. L., Desai, A. S., Petersson, M., Langkilde, A. M., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Køber, L., Lam, C. S. P., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Shah, S. J., Vaduganathan, M., Jhund, P. S., Solomon, S. D., McMurray, J. J.V. (2023) Association of dapagliflozin use with clinical outcomes and the introduction of uric acid–lowering therapy and colchicine in patients with heart failure with and without gout. JAMA Cardiology, 8, pp. 386-393. (doi: 10.1001/jamacardio.2022.5608)

Butt, J. H. et al. (2023) Dapagliflozin in Black and White patients with heart failure across the ejection fraction spectrum. JACC: Heart Failure, 11, pp. 375-388. (doi: 10.1016/j.jchf.2022.11.014)

Adamson, C., Welsh, P., Docherty, K. F., de Boer, R. A., Diez, M., Drożdż, J., Dukát, A., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Ljungman, C. E.A., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Morrow, D. A., Lindholm, D., Hammarstedt, A., Boulton, D. W., Greasley, P. J., Langkilde, A. M., Solomon, S. D., Sattar, N., McMurray, J. J.V., Jhund, P. S. (2023) IGFBP-7 and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. JACC: Heart Failure, 11, pp. 291-304. (doi: 10.1016/j.jchf.2022.09.004)

Docherty, K. F., Jhund, P. S. (2023) A welcome ‘failure’ of gliflozins: blood pressure reduction in heart failure. European Heart Journal, 44, pp. 408-410. (doi: 10.1093/eurheartj/ehac712)

Docherty, K. F., McMurray, J. J.V., Claggett, B. L., Miao, Z. M., Adams, K. F., Arias‐Mendoza, A., Cleland, J. G.F., Diaz, R., Echeverría Correa, L. E., Felker, G. M., Fonseca, C., Li, J., Metra, M., Sliwa‐Hahnle, K., Solomon, S. D., Vandekerckhove, H. J., Vinereanu, D., Voors, A. A., Heitner, S. B., Kupfer, S., Malik, F. I., Meng, L., Teerlink, J. R. (2023) Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N‐terminal pro‐B ‐type natriuretic peptide level: insights from the GALACTIC‐HF trial. European Journal of Heart Failure, 25, pp. 248-259. (doi: 10.1002/ejhf.2763)

Mc Causland, F. R., Claggett, B. L., Vaduganathan, M., Desai, A. S., Jhund, P., de Boer, R. A., Docherty, K., Fang, J., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Saraiva, J. F. K., McGrath, M. M., Shah, S. J., Verma, S., Langkilde, A. M., Petersson, M., McMurray, J. J. V., Solomon, S. D. (2023) Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction. JAMA Cardiology, 8, pp. 56-65. (doi: 10.1001/jamacardio.2022.4210)

Lee, M. M.Y., Campbell, R. T., Claggett, B. L., Lewis, E. F., Docherty, K. F., Lindner, M., Liu, J., Solomon, S. D., McMurray, J. J.V., Platz, E. (2023) Health‐related quality of life in acute heart failure: association between patient‐reported symptoms and markers of congestion. European Journal of Heart Failure, 25, pp. 54-60. (doi: 10.1002/ejhf.2699)

Yang, M., Butt, J. H., Kondo, T., Jering, K. S., Docherty, K. F., Jhund, P. S., de Boer, R. A., Claggett, B. L., Desai, A. S., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S.P., Langkilde, A. M., Martinez, F. A., Petersson, M., Shah, S. J., Vaduganathan, M., Wilderäng, U., Solomon, S. D., McMurray, J. J.V. (2022) Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan. European Journal of Heart Failure, 24, pp. 2307-2319. (doi: 10.1002/ejhf.2722)

Sun, G., Yafasova, A., Andersson, C., McMurray, J. J.V., Jhund, P. S., Docherty, K. F., Faurschou, M., Nielsen, C. T., Schou, M., Gislason, G. H., Torp-Pedersen, C., Fosbøl, E. L., Køber, L., Butt, J. H. (2022) Gender- and age-specific rates of heart failure and other adverse cardiovascular outcomes in systemic sclerosis. Rheumatology, 61, pp. 4374-4383. (doi: 10.1093/rheumatology/keac072)

Ferreira, J. P., Claggett, B. L., Docherty, K. F., Jhund, P. S., Zannad, F., Solomon, S. D., McMurray, J. J.V. (2022) Within trial comparison of survival time projections from short-term follow-up with long-term follow-up findings. ESC Heart Failure, 9, pp. 3655-3658. (doi: 10.1002/ehf2.13731)

Docherty, K. F., Welsh, P., Verma, S., De Boer, R. A., O'Meara, E., Bengtsson, O., Køber, L., Kosiborod, M. N., Hammarstedt, A., Langkilde, A. M., Lindholm, D., Little, D. J., Sjöstrand, M., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Morrow, D. A., Schou, M., Solomon, S. D., Sattar, N., Jhund, P. S., McMurray, J. J.V. (2022) Iron deficiency in heart failure and effect of dapagliflozin: findings from DAPA-HF. Circulation, 146, pp. 980-994. (doi: 10.1161/CIRCULATIONAHA.122.060511)

Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S.P., Martinez, F., Shah, S. J., Desai, A. S., McMurray, J. J.V., Solomon, S. D. (2022) SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet, 400, pp. 757-767. (doi: 10.1016/S0140-6736(22)01429-5)

Jhund, P. S., Kondo, T., Butt, J. H., Docherty, K. F., Claggett, B. L., Desai, A. S., Vaduganathan, M., Gasparyan, S. B., Bengtsson, O., Lindholm, D., Petersson, M., Langkilde, A. M., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Køber, L., Lam, C. S. P., Martinez, F. A., Sabatine, M. S., Shah, S. J., Solomon, S. D., McMurray, J. J. V. (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature Medicine, 28, pp. 1956-1964. (doi: 10.1038/s41591-022-01971-4)

Adamson, C., Docherty, K. F., Heerspink, H. J.L., de Boer, R. A., Damman, K., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Petrie, M. C., Ponikowski, P., Sabatine, M. S., Schou, M., Solomon, S. D., Verma, S., Bengtsson, O., Langkilde, A. M., Sjöstrand, M., Vaduganathan, M., Jhund, P. S., McMurray, J. J.V. (2022) Initial decline ("dip") in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation, 146, pp. 438-449. (doi: 10.1161/CIRCULATIONAHA.121.058910)

Butt, J. H., Dewan, P., DeFilippis, E. M., Biering-Sørensen, T., Docherty, K. F., Jhund, P. S., Kosiborod, M. N., Martinez, F. A., Bengtsson, O., Johansen, N. D., Langkilde, A. M., Sjöstrand, M., Vaduganathan, M., Solomon, S. D., Sabatine, M. S., Køber, L., Fiuzat, M., McMurray, J. J.V. (2022) Effects of dapagliflozin according to the heart failure collaboratory medical therapy score insights from DAPA-HF. JACC: Heart Failure, 10, pp. 543-555. (doi: 10.1016/j.jchf.2022.03.009)

Lee, M. M.Y. et al. (2022) Effect of empagliflozin on kidney biochemical and imaging outcomes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF) Circulation, 146, pp. 364-367. (doi: 10.1161/CIRCULATIONAHA.122.059851)

Lewis, G. D., Voors, A. A., Cohen-Solal, A., Metra, M., Whellan, D. J., Ezekowitz, J. A., Böhm, M., Teerlink, J. R., Docherty, K. F., Lopes, R. D., Divanji, P. H., Heitner, S. B., Kupfer, S., Malik, F. I., Meng, L., Wohltman, A., Felker, G. M. (2022) Effect of omecamtiv mecarbil on exercise capacity in chronic heart failure with reduced ejection fraction. JAMA: Journal of the American Medical Association, 328, pp. 259-269. (doi: 10.1001/jama.2022.11016)

Shen, L., Jhund, P. S., Docherty, K. F., Vaduganathan, M., Petrie, M. C., Desai, A. S., Køber, L., Schou, M., Packer, M., Solomon, S. D., Zhang, X., McMurray, J. J. V. (2022) Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal, 43, pp. 2573-2587. (doi: 10.1093/eurheartj/ehac210)

McDowell, K., Docherty, K. F. (2022) Sodium-glucose cotransporter 2 inhibitors: the first universal treatment for heart failure? European Heart Journal: Quality of Care and Clinical Outcomes, 8, pp. 371-373. (doi: 10.1093/ehjqcco/qcab088)

Fernando, J., Lee, M., Quinn, D., Corcoran, D., Connolly, E. (2022) Assessing the Impact of the Covid-19 Pandemic on Rapid Access Chest Pain Clinics: A Retrospective Audit in Glasgow. (doi: 10.1136/heartjnl-2022-BCS.70)

McDowell, K., Welsh, P., Docherty, K. F., Morrow, D. A., Jhund, P. S., De Boer, R. A., O’Meara, E., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Hammarstedt, A., Langkilde, A. M., Sjöstrand, M., Lindholm, D., Solomon, S. D., Sattar, N., Sabatine, M. S., McMurray, J. J.V. (2022) Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF. European Journal of Heart Failure, 24, pp. 1066-1076. (doi: 10.1002/ejhf.2433)

Butt, J. H., Dewan, P., Merkely, B., Belohlávek, J., Drożdż, J., Kitakaze, M., Inzucchi, S. E., Kosiborod, M. N., Martinez, F. A., Tereshchenko, S., Ponikowski, P., Bengtsson, O., Lindholm, D., Langkilde, A. M., Schou, M., Sjöstrand, M., Solomon, S. D., Sabatine, M. S., Chiang, C.-E., Docherty, K. F., Jhund, P. S., Køber, L., McMurray, J. J.V. (2022) Efficacy and safety of dapagliflozin according to frailty in heart failure with reduced ejection fraction. Annals of Internal Medicine, 175, pp. 820-830. (doi: 10.7326/m21-4776)

McMurray, J. J.V., Docherty, K. F. (2022) Insights into foundational therapies for heart failure with reduced ejection fraction. Clinical Cardiology, 45, pp. S26-S30. (doi: 10.1002/clc.23847)

Jhund, P. S., Docherty, K. F., McMurray, J. J.V. (2022) Age-adjusted survival extrapolations—results may differ from those generated by the Weibull model—reply. JAMA Cardiology, 7, pp. 570. (doi: 10.1001/jamacardio.2021.6032)

Lewis, G. D., Docherty, K. F., Voors, A. A., Cohen-Solal, A., Metra, M., Whellan, D. J., Ezekowitz, J. A., Ponikowski, P., Böhm, M., Teerlink, J. R., Heitner, S. B., Kupfer, S., Malik, F. I., Meng, L., Felker, G. M. (2022) Developments in exercise capacity assessment in heart failure clinical trials and the rationale for the design of METEORIC-HF. Circulation: Heart Failure, 15, (doi: 10.1161/CIRCHEARTFAILURE.121.008970)

Butt, J. H., Adamson, C., Docherty, K. F., Vaduganathan, M., Solomon, S. D., Anand, I. S., Zannad, F., Køber, L., Jhund, P. S., McMurray, J. J.V. (2022) Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new CKD-EPI creatinine equation for estimating glomerular filtration rate. European Journal of Heart Failure, 24, pp. 861-866. (doi: 10.1002/ejhf.2460)

He, W. et al. (2022) Inhibition of myocardial cathepsin-L release during reperfusion following myocardial infarction improves cardiac function and reduces infarct size. Cardiovascular Research, 118, pp. 1535-1547. (doi: 10.1093/cvr/cvab204)

Yeoh, S. E., Docherty, K. F., Jhund, P. S., Petrie, M. C., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Bengtsson, O., Boulton, D. W., Greasley, P. J., Langkilde, A. M., Sjöstrand, M., Solomon, S. D., McMurray, J. J.V. (2022) Relationship of dapagliflozin with serum sodium: findings from the DAPA-HF trial. JACC: Heart Failure, 10, pp. 306-318. (doi: 10.1016/j.jchf.2022.01.019)

Lee, M. M.Y., Docherty, K. F., Jhund, P. S. (2022) Sodium–glucose co-transporter-2 inhibitors. Oxford University Press

Docherty, K. F., Anand, I. S., Chiang, C.-E., Chopra, V. K., Desai, A. S., Kitakaze, M., Verma, S., Vinh, P. N., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sabatine, M. S., Sjöstrand, M., Solomon, S. D., Langkilde, A. M., Jhund, P. S., McMurray, J. J.V. (2022) Effects of dapagliflozin in Asian patients with heart failure and reduced ejection fraction in DAPA-HF. JACC: Asia, 2, pp. 139-153. (doi: 10.1016/j.jacasi.2022.02.004)

Butt, J. H., Docherty, K. F., Jhund, P. S., De Boer, R. A., Böhm, M., Desai, A. S., Howlett, J. G., Inzucchi, S. E., Kosiborod, M. N., Martinez, F. A., Nicolau, J. C., Petrie, M. C., Ponikowski, P., Bengtsson, O., Langkilde, A. M., Schou, M., Sjöstrand, M., Solomon, S. D., Sabatine, M. S., McMurray, J. J.V., Køber, L. (2022) Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. European Journal of Heart Failure, 24, pp. 513-525. (doi: 10.1002/ejhf.2381)

Curtain, J. P., Jackson, A., Shen, L., Jhund, P. S., Docherty, K. F., Petrie, M. C., Castagno, D., Desai, A. S., Rohde, L. E., Lefkowitz, M. P., Rouleau, J.-L., Zile, M. R., Solomon, S. D., Swedberg, K., Packer, M., McMurray, J. J.V. (2022) Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF. European Journal of Heart Failure, 24, pp. 551-561. (doi: 10.1002/ejhf.2419)

Lee, M. M.Y., Docherty, K. F., Sattar, N., Mehta, N., Kalra, A., Nowacki, A. S., Solomon, S. D., Vaduganathan, M., Petrie, M. C., Jhund, P. S., McMurray, J. J.V. (2022) Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. European Heart Journal: Cardiovascular Pharmacotherapy, 8, pp. 165-178. (doi: 10.1093/ehjcvp/pvaa138)

Docherty, K. F., Petrie, M. C. (2022) Sodium-glucose cotransporter 2 inhibitors as a treatment for heart failure. Heart, 108, pp. 312-320. (doi: 10.1136/heartjnl-2020-318658)

Berg, D. D., Docherty, K. F., Sattar, N., Jarolim, P., Welsh, P., Jhund, P. S., Anand, I. S., Chopra, V., de Boer, R. A., Kosiborod, M. N., Nicolau, J. C., O'Meara, E., Schou, M., Hammarstedt, A., Langkilde, A.-M., Lindholm, D., Sjöstrand, M., McMurray, J. J.V., Sabatine, M. S., Morrow, D. A. (2022) Serial assessment of high-sensitivity cardiac troponin and the effect of dapagliflozin in patients with heart failure with reduced ejection fraction: an analysis of the DAPA-HF trial. Circulation, 145, pp. 158-169. (doi: 10.1161/CIRCULATIONAHA.121.057852)

Lee, M. M.Y., Kristensen, S. L., Gerstein, H. C., McMurray, J. J.V., Sattar, N. (2022) Cardiovascular and mortality outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a meta-analysis with the FREEDOM cardiovascular outcomes trial. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 16, (doi: 10.1016/j.dsx.2021.102382)

Rossing, P. et al. (2022) Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes and Endocrinology, 10, pp. 24-34. (doi: 10.1016/S2213-8587(21)00295-3)

Butt, J. H., Adamson, C., Docherty, K. F., de Boer, R. A., Petrie, M. C., Inzucchi, S. E., Kosiborod, M. N., Maria Langkilde, A., Lindholm, D., Martinez, F. A., Bengtsson, O., Schou, M., O’Meara, E., Ponikowski, P., Sabatine, M. S., Sjöstrand, M., Solomon, S. D., Jhund, P. S., McMurray, J. J.V., Køber, L. (2021) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: insights from the DAPA-HF trial. Circulation: Heart Failure, 14, (doi: 10.1161/CIRCHEARTFAILURE.121.008837)

Docherty, K. F., Jhund, P. S., Claggett, B., Ferreira, J. P., Bengtsson, O., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Sjöstrand, M., Solomon, S. D., McMurray, J. J.V. (2021) Extrapolating long-term event-free and overall survival with dapagliflozin in patients with heart failure and reduced ejection fraction: an exploratory analysis of a phase 3 randomized clinical trial. JAMA Cardiology, 6, pp. 1298-1305. (doi: 10.1001/jamacardio.2021.2632)

Lee, M., Campbell, R. T., Claggett, B.L., Lewis, E.F., Groarke, J.D., Docherty, K. F., Lindner, M., Liu, J., Soloman, S.D., McMurray, J. J.V., Platz, E. (2021) Lung Ultrasound in Acute Heart Failure: Association Between Quality of Life, Symptoms and B-Lines. (doi: 10.1093/eurheartj/ehab724.1043)

Sattar, N., Lee, M. M.Y., Kristensen, S. L., Branch, K. R.H., Del Prato, S., Khurmi, N. S., Lam, C. S.P., Lopes, R. D., McMurray, J. J.V., Pratley, R. E., Rosenstock, J., Gerstein, H. C. (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes and Endocrinology, 9, pp. 653-662. (doi: 10.1016/S2213-8587(21)00203-5)

Adamson, C., Jhund, P. S., Docherty, K. F., Bělohlávek, J., Chiang, C.‐E., Diez, M., Drożdż, J., Dukát, A., Howlett, J., Ljungman, C. E.A., Petrie, M. C., Schou, M., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Solomon, S. D., Bengtsson, O., Langkilde, A. M., Lindholm, D., Sjöstrand, M., McMurray, J. J.V. (2021) Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European Journal of Heart Failure, 23, pp. 1662-1672. (doi: 10.1002/ejhf.2308)

Curtain, J. P., Docherty, K. F., Jhund, P. S., Petrie, M. C., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F., Ponikowski, P., Sabatine, M. S., Bengtsson, O., Langkilde, A. M., Sjöstrand, M., Solomon, S. D., McMurray, J. J.V. (2021) Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal, 42, pp. 3727-3738. (doi: 10.1093/eurheartj/ehab560)

Petrie, M. C., Lee, M. M.Y., Docherty, K. F. (2021) Sodium–glucose co-transporter 2 inhibitors—the first successful treatment for heart failure with preserved ejection fraction? European Journal of Heart Failure, 23, pp. 1256-1259. (doi: 10.1002/ejhf.2108)

Lee, M. M.Y., McMurray, J. J.V., Jhund, P. S., Petrie, M. C., Sattar, N. (2021) Response by Lee et al to letter regarding article, "Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)" Circulation, 144, pp. e40. (doi: 10.1161/CIRCULATIONAHA.121.055067)

Docherty, K. F., Campbell, R. T., Brooksbank, K. J.M., Dreisbach, J. G., Forsyth, P., Godeseth, R., Hopkins, T., Jackson, A. M., Lee, M. M.Y., McConnachie, A., Roditi, G., Squire, I. B., Stanley, B., Welsh, P., Jhund, P. S., Petrie, M., McMurray, J. J.V. (2021) The effect of neprilysin inhibition on left ventricular remodeling in patients with asymptomatic left ventricular systolic dysfunction late after myocardial infarction. Circulation, 144, pp. 199-209. (doi: 10.1161/CIRCULATIONAHA.121.054892)

Butt, J. H., Docherty, K. F., Petrie, M. C., Schou, M., Kosiborod, M. N., O’Meara, E., Katova, T., Ljungman, C. E.A., Diez, M., Ogunniyi, M. O., Langkilde, A. M., Sjöstrand, M., Lindholm, D., Bengtsson, O., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Solomon, S. D., Jhund, P. S., McMurray, J. J.V., Køber, L. (2021) Efficacy and safety of dapagliflozin in men and women with heart failure with reduced ejection fraction: results from the DAPA-HF trial. JAMA Cardiology, 6, pp. 678-689. (doi: 10.1001/jamacardio.2021.0379)

Espersen, C., Campbell, R. T., Claggett, B., Lewis, E. F., Groarke, J. D., Docherty, K. F., Lee, M. M.Y., Lindner, M., Biering‐Sørensen, T., Solomon, S. D., McMurray, J. J.V., Platz, E. (2021) Sex differences in congestive markers in patients hospitalized for acute heart failure. ESC Heart Failure, 8, pp. 1784-1795. (doi: 10.1002/ehf2.13300)

Jhund, P. S., Ponikowski, P., Docherty, K. F., Gasparyan, S. B., Böhm, M., Chang, C.-E., Desai, A. S., Howlett, J., Kitakaze, M., Petrie, M. C., Verma, S., Bengtsson, O., Langkilde, A.-M., Sjöstrand, M., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Sabatine, M. S., Solomon, S. D., McMurray, J. J.V. (2021) Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF. Circulation, 143, pp. 1962-1972. (doi: 10.1161/CIRCULATIONAHA.121.053659)

Lee, M. M.Y., Ghouri, N., McGuire, D. K., Rutter, M. K., Sattar, N. (2021) Meta-analyses of results from randomized outcome trials comparing cardiovascular effects of SGLT2i and GLP-1RA in Asian vs. White patients with and without type 2 diabetes. Diabetes Care, 44, pp. 1236-1241. (doi: 10.2337/dc20-3007)

Berg, D. D., Jhund, P. S., Docherty, K. F., Murphy, S. A., Verma, S., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Bengtsson, O., Ponikowski, P., Sjöstrand, M., Solomon, S. D., McMurray, J. J.V., Sabatine, M. S. (2021) Time to clinical benefit of dapagliflozin and significance of prior heart failure hospitalization in patients with heart failure with reduced ejection fraction. JAMA Cardiology, 6, pp. 499-507. (doi: 10.1001/jamacardio.2020.7585)

McMurray, J. J.V., Solomon, S. D., Docherty, K. F., Jhund, P. S. (2021) The Dapagliflozin And Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context. European Heart Journal, 42, pp. 1199-1202. (doi: 10.1093/eurheartj/ehz916)

Docherty, K. F., Curtain, J. P., Anand, I. S., Bengtsson, O., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Sjöstrand, M., Solomon, S. D., Jhund, P. S., McMurray, J. J.V. (2021) Effect of dapagliflozin on anaemia in DAPA-HF. European Journal of Heart Failure, 23, pp. 617-628. (doi: 10.1002/ejhf.2132)

Dewan, P., Docherty, K. F., Bengtsson, O., de Boer, R. A., Desai, A. S., Drozdz, J., Hawkins, N. M., Inzucchi, S. E., Kitakaze, M., Køber, L., Kosiborod, M. N., Langkilde, A. M., Lindholm, D., Martinez, F. A., Merkely, B., Petrie, M. C., Ponikowski, P., Sabatine, M. S., Schou, M., Sjöstrand, M., Solomon, S. D., Verma, S., Jhund, P. S., McMurray, J. J.V. (2021) Effects of dapagliflozin in heart failure with reduced ejection fraction, and chronic obstructive pulmonary disease: an analysis of DAPA-HF. European Journal of Heart Failure, 23, pp. 632-643. (doi: 10.1002/ejhf.2083)

Butt, J. H., Nicolau, J. C., Verma, S., Docherty, K. F., Petrie, M. C., Inzucchi, S. E., Schou, M., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Sjöstrand, M., Solomon, S. D., Bengtsson, O., Jhund, P. S., McMurray, J., Køber, L. (2021) Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European Journal of Heart Failure, 23, pp. 601-613. (doi: 10.1002/ejhf.2124)

Lee, M. M.Y. et al. (2021) Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations. Open Heart, 8, (doi: 10.1136/openhrt-2020-001453)

Lee, M. M.Y. et al. (2021) Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF) Circulation, 143, pp. 516-525. (doi: 10.1161/CIRCULATIONAHA.120.052186)

Petrie, M. C., Lee, M. M., Lang, N. N. (2021) EMPEROR-REDUCED reigns while EMPERIAL whimpers. European Heart Journal, 42, pp. 711-714. (doi: 10.1093/eurheartj/ehaa965)

Inzucchi, S. E., Docherty, K. F., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Solomon, S. D., Verma, S., Bělohlávek, J., Böhm, M., Chiang, C.-E., de Boer, R. A., Diez, M., Dukát, A., Ljungman, C. E.A., Bengtsson, O., Langkilde, A. M., Sjöstrand, M., Jhund, P. S., McMurray, J. J.V. (2021) Dapagliflozin and the incidence of type 2 diabetes in patients with heart failure and reduced ejection fraction: an exploratory analysis from DAPA-HF. Diabetes Care, 44, pp. 586-594. (doi: 10.2337/dc20-1675)

Docherty, K. F., Campbell, R. T., Brooksbank, K. J.M., Godeseth, R. L., Forsyth, P., McConnachie, A., Roditi, G., Stanley, B., Welsh, P., Jhund, P. S., Petrie, M. C., McMurray, J. J.V. (2021) Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling. ESC Heart Failure, 8, pp. 129-138. (doi: 10.1002/ehf2.13137)

Jhund, P. S. et al. (2021) Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF. Circulation, 143, pp. 289-309. (doi: 10.1161/CIRCULATIONAHA.120.050391)

Docherty, K. F., Vaduganathan, M. (2021) OUTSTEP‐HF: re‐evaluating the role of physical activity measures in drug and device development in heart failure. European Journal of Heart Failure, 23, pp. 136-139. (doi: 10.1002/ejhf.2106)

McMurray, J. J.V., Docherty, K. F. (2021) SOLOIST-WHF: Sodium-glucose cotransporter 2 (SGLT2) inhibitors should be initiated in patients hospitalised with worsening heart failure. European Journal of Heart Failure, 23, pp. 27-30. (doi: 10.1002/ejhf.2075)

Lee, M. (2020) Studies of Empagliflozin and its Cardiovascular, Renal and Metabolic Effects in Patients With Diabetes Mellitus (or Prediabetes) and Heart Failure: a Randomized Controlled Trial (SUGAR-DM-HF) (doi: 10.1161/CIR.0000000000000940)

Mangion, K., Loughrey, C., Auger, D. A., McComb, C., Lee, M. M., Corcoran, D., McEntegart, M., Davie, A., Good, R., Lindsay, M., Eteiba, H., Rocchiccioli, J. P., Watkins, S., Hood, S., Shaukat, A., Haig, C., Epstein, F. H., Berry, C. (2020) Displacement encoding with stimulated echoes enables the identification of infarct transmurality early postmyocardial infarction. Journal of Magnetic Resonance Imaging, 52, pp. 1722-1731. (doi: 10.1002/jmri.27295)

Ferreira, J. P., Docherty, K. F., Stienen, S., Jhund, P. S., Claggett, B. L., Solomon, S. D., Petrie, M. C., Gregsone, J., Pocock, S. L., Zannad, F., McMurray, J. (2020) Estimating the lifetime benefits of treatments for heart failure. JACC: Heart Failure, 8, pp. 984-995. (doi: 10.1016/j.jchf.2020.08.004)

Kristensen, S. L., Castagno, D., Shen, L., Jhund, P., Docherty, K., Rørth, R., Abraham, W. T., Desai, A., Dickstein, K., Rouleau, J. L., Zile, M. R., Swedberg, K., Packer, M., Solomon, S. D., Køber, L., McMurray, J. J.V. (2020) Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM‐HF and ATMOSPHERE. European Journal of Heart Failure, 22, pp. 2370-2379. (doi: 10.1002/ejhf.1972)

McEwan, P., Darlington, O., McMurray, J. J.V., Jhund, P. S., Docherty, K. F., Böhm, M., Petrie, M. C., Bergenheim, K., Qin, L. (2020) Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. European Journal of Heart Failure, 22, pp. 2147-2156. (doi: 10.1002/ejhf.1978)

Docherty, K., Jhund, P. S., Bengtsson, O., DeMets, D. L., Inzucchi, S. E., Kober, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Sabatine, M. S., Sjöstrand, M., Solomon, S. D., McMurray, J. J.V. (2020) Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy. Diabetes Care, 43, pp. 2878-2881. (doi: 10.2337/dc20-1402)

Docherty, K. F. et al. (2020) Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: a prespecified analysis of DAPA-HF. Circulation, 142, pp. 1623-1632. (doi: 10.1161/CIRCULATIONAHA.120.047480)

Docherty, K. F., Vaduganathan, M., Solomon, S. D., McMurray, J. J.V. (2020) Sacubitril/valsartan: neprilysin inhibition 5 Years after PARADIGM-HF. JACC: Heart Failure, 8, pp. 800-810. (doi: 10.1016/j.jchf.2020.06.020)

Serenelli, M. et al. (2020) Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF) European Heart Journal, 41, pp. 3402-3418. (doi: 10.1093/eurheartj/ehaa496)

Jackson, A. M. et al. (2020) Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF. Circulation, 142, pp. 1040-1054. (doi: 10.1161/CIRCULATIONAHA.120.047077)

Docherty, K. F., Jhund, P. S., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., DeMets, D. L., Sabatine, M. S., Bengtsson, O., Sjöstrand, M., Langkilde, A. M., Desai, A. S., Diez, M., Howlett, J. G., Katova, T., Ljungman, C. E. A., O’Meara, E., Petrie, M. C., Schou, M., Verma, S., Vinh, P. N., Solomon, S. D., McMurray, J. J.V. (2020) Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. European Heart Journal, 41, pp. 2379-2392. (doi: 10.1093/eurheartj/ehaa183)

Docherty, K. F., Ferreira, J. P., Sharma, A., Girerd, N., Gregson, J., Duarte, K., Petrie, M. C., Jhund, P. S., Dickstein, K., Pfeffer, M. A., Pitt, B., Rossignol, P., Zannad, F., McMurray, J. J.V. (2020) Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. European Journal of Heart Failure, 22, pp. 848-855. (doi: 10.1002/ejhf.1694)

Petrie, M. C., et al. (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA: Journal of the American Medical Association, 323, pp. 1353-1368. (doi: 10.1001/jama.2020.1906)

Lee, M. M.Y., Petrie, M. C., McMurray, J. J.V., Sattar, N. (2020) How do SGLT2 (sodium-glucose cotransporter 2) inhibitors and GLP-1 (glucagon-like peptide-1) receptor agonists reduce cardiovascular outcomes? Arteriosclerosis, Thrombosis, and Vascular Biology, 40, pp. 506-522. (doi: 10.1161/atvbaha.119.311904)

Docherty, K. F., Shen, L., Castagno, D., Petrie, M. C., Abraham, W. T., Böhm, M., Desai, A. S., Dickstein, K., Køber, L. V., Packer, M., Rouleau, J. L., Solomon, S. D., Swedberg, K., Vazir, A., Zile, M. R., Jhund, P. S., McMurray, J. J.V. (2020) Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. European Journal of Heart Failure, 22, pp. 528-538. (doi: 10.1002/ejhf.1682)

Rankin, A. J., Allwood-Spiers, S., Lee, M. M.Y., Zhu, L., Woodward, R., Kuehn, B., Radjenovic, A., Sattar, N., Roditi, G., Mark, P. B., Gillis, K. A. (2020) Comparing the interobserver reproducibility of different regions of interest on multi-parametric renal magnetic resonance imaging in healthy volunteers, patients with heart failure and renal transplant recipients. Magnetic Resonance Materials in Physics, Biology and Medicine, 33, pp. 103-112. (doi: 10.1007/s10334-019-00809-4)

Kosiborod, M. N., Jhund, P., Docherty, K. F., Diez, M., Petrie, M. C., Verma, S., Nicolau, J. C., Merkely, B., Kitakaze, M., DeMets, D. L., Inzucchi, S. E., Køeber, L., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Solomon, S. D., Bengtsson, O., Lindholm, D., Niklasson, A., Sjöstrand, M., Langkilde, A. M., McMurray, J. J.V. (2020) Effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial. Circulation, 141, pp. 90-99. (doi: 10.1161/CIRCULATIONAHA.119.044138)

Sharma, V. et al. (2019) Report from the Annual Conference of the British Society of Echocardiography, November 2017, Edinburgh International Conference Centre, Edinburgh. Echo Research and Practice, 6, pp. M1-M2. (doi: 10.1530/ERP-19-0056)

McMurray, J. J.V. et al. (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. New England Journal of Medicine, 381, pp. 1995-2008. (doi: 10.1056/NEJMoa1911303)

Docherty, K. F., McMurray, J. J.V. (2019) PIONEER-HF: a new frontier in the role of neprilysin inhibition in the management of heart failure with reduced ejection fraction. Cardiovascular Research, 115, pp. e136-e139. (doi: 10.1093/cvr/cvz223)

Platz, E., Campbell, R. T., Claggett, B., Lewis, E. F., Groarke, J. D., Docherty, K. F., Lee, M. M.Y., Merz, A. A., Silverman, M., Swamy, V., Lindner, M., Rivero, J., Solomon, S. D., McMurray, J. J.V. (2019) Lung ultrasound in acute heart failure: prevalence of pulmonary congestion and short- and long-term outcomes. JACC: Heart Failure, 7, pp. 849-858. (doi: 10.1016/j.jchf.2019.07.008)

Lee, M. M.Y., Sattar, N., McMurray, J. J.V., Packard, C. J. (2019) Statins in the prevention and treatment of heart failure: a review of the evidence. Current Atherosclerosis Reports, 21, (doi: 10.1007/s11883-019-0800-z)

Kristensen, S. L., Rorth, R., Jhund, P. S., Docherty, K., Sattar, N., Preiss, D., Kober, L., Petrie, M. C., McMurray, J. J.V. (2019) Cardiovascular, mortality and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology, 7, pp. 776-785. (doi: 10.1016/S2213-8587(19)30249-9)

McMurray, J. J.V., Docherty, K. F. (2019) Phosphodiesterase-9 inhibition in heart failure: a further opportunity to augment the effects of natriuretic peptides? Journal of the American College of Cardiology, 74, pp. 902-904. (doi: 10.1016/j.jacc.2019.07.008)

Lee, M. M.Y. et al. (2019) Invasive versus medical management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: a pilot randomized controlled trial. Circulation: Cardiovascular Interventions, 12, (doi: 10.1161/CIRCINTERVENTIONS.119.007830)

Dewan, P., Docherty, K. F., McMurray, J. J.V. (2019) Sacubitril/valsartan in Asian patients with heart failure with reduced ejection fraction. Korean Circulation Journal, 49, pp. 469-484. (doi: 10.4070/kcj.2019.0136)

Shen, L., Jhund, P. S., Docherty, K. F., Petrie, M. C., Anand, I. S., Carson, P. E., Desai, A. S., Granger, C. B., Komajda, M., McKelvie, R. S., Pfeffer, M. A., Solomon, S. D., Swedberg, K., Zile, M. R., McMurray, J. J.V. (2019) Prior pacemaker implantation and clinical outcomes in patients with heart failure and preserved ejection fraction. JACC: Heart Failure, 7, pp. 418-427. (doi: 10.1016/j.jchf.2018.12.006)

Docherty, K. F., McMurray, J. J.V. (2019) Angiotensin receptor-neprilysin inhibitors: a new paradigm in heart failure with reduced ejection fraction. International Journal of Cardiology, 281, pp. 179-185. (doi: 10.1016/j.ijcard.2018.05.124)

Lee, M. M.Y., Campbell, R. T., Kelly, R., Petrie, M. C., Sonecki, P. (2019) Does “Scar” at Rest Echocardiography Predict Lack of Contractility Reserve at Dobutamine Stress Echocardiography. (doi: 10.1093/ehjci/jey266)

Lee, M. M. Y., McMurray, J. J.V., Lorenzo-Almorós, A., Kristensen, S. L., Sattar, N., Jhund, P. S., Petrie, M. C. (2019) Diabetic cardiomyopathy. Heart, 105, pp. 337-345. (doi: 10.1136/heartjnl-2016-310342)

Docherty, K. F., Jhund, P. S. (2018) Early use of mineralocorticoid receptor antagonists in ST-elevation myocardial infarction: is it ever too early? Heart, 104, pp. 1812-1813. (doi: 10.1136/heartjnl-2018-313371)

Kristensen, S. L., Rørth, R., Jhund, P. S., Shen, L., Lee, M. M.Y., Petrie, M. C., Køber, L., McMurray, J. J.V. (2018) Microvascular complications in diabetes patients with heart failure and reduced ejection fraction-insights from the Beta-blocker Evaluation of Survival Trial. European Journal of Heart Failure, 20, pp. 1549-1556. (doi: 10.1002/ejhf.1201)

Docherty, K. F., Jhund, P. S., McMurray, J. J.V. (2018) Catheter ablation for atrial fibrillation with heart failure. New England Journal of Medicine, 379, pp. 491-492. (doi: 10.1056/NEJMc1806519)

Lee, M. M.Y. et al. (2018) Non-Invasive Versus Invasive Management in Patients With Prior Coronary Artery Bypass Surgery With a Non-ST Segment Elevation Acute Coronary Syndrome: Comparisons Between the Randomized Controlled Pilot Trial and Registry. (doi: 10.1016/S0735-1097(18)30586-2)

Lee, M. M.Y. et al. (2018) Routine Non-invasive vs Invasive Management in Patients With Prior CABG With a NSTE-ACS: a Randomised Controlled Trial. (doi: 10.1136/heartjnl-2018-BCIS.9)

Layland, J., Tong, D., Lee, M., Berry, C. (2018) ST and T-Wave Abnormality as Footprint of Myocardial Oedema in Non–ST-Elevation Myocardial Infarction. (doi: 10.1016/j.hlc.2018.06.515)

Kristensen, S. L., Jhund, P. S., Lee, M. M.Y., Køber, L., Solomon, S. D., Granger, C. B., Yusuf, S., Pfeffer, M. A., Swedberg, K., McMurray, J. J.V. (2017) Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes. Cardiovascular Drugs and Therapy, 31, pp. 545-549. (doi: 10.1007/s10557-017-6754-x)

Layland, J., Rauhalammi, S., Lee, M. M.Y., Ahmed, N., Carberry, J., Teng Yue May, V., Watkins, S., McComb, C., Mangion, K., McClure, J. D., Carrick, D., O'Donnell, A., Sood, A., McEntegart, M., Oldroyd, K. G., Radjenovic, A., Berry, C. (2017) Diagnostic accuracy of 3.0-T magnetic resonance T1 and T2 mapping and T2-weighted dark-blood imaging for the infarct-related coronary artery in Non-ST-segment elevation myocardial infarction. Journal of the American Heart Association, 6, (doi: 10.1161/JAHA.116.004759)

Layland, J. J., Carberry, J., May, V. T.Y., Lee, M., Eteiba, H., Lindsay, M., Petrie, M., McEntegart, M., Watkins, S., Shaukat, A., Oldroyd, K., Curzen, N., Sood, A., Balachandran, K., Das, R., Junejo, S., Hannah, A., Stewart, A., Henderson, R., McConnachie, A., Berry, C. (2017) Decision Making Using Fractional Flow Reserve is Associated With Lower Rates of Incomplete Revascularization Compared With Angiographic Guided Decision Making Amongst Patients With NSTEMI. (doi: 10.1016/s0735-1097(17)34446-7)

Docherty, K. F., Campbell, R. T., Jhund, P., Petrie, M. C., McMurray, J. J.V. (2017) How robust are clinical trials in heart failure? European Heart Journal, 38, pp. 338-345. (doi: 10.1093/eurheartj/ehw427)

Wilson, M. R., Docherty, K. F., Gardner, R. S. (2016) Use of direct oral anticoagulants in thromboembolic disease. Prescriber, 27, pp. 15-22. (doi: 10.1002/psb.1487)

Lee, M. M.Y., Petrie, M. C., Rocchiccioli, P., Simpson, J., Jackson, C., Brown, A., Corcoran, D., Mangion, K., McEntegart, M., Shaukat, A., Rae, A., Hood, S., Peat, E., Findlay, I., Murphy, C., Cormack, A., Bukov, N., Balachandran, K., Papworth, R., Ford, I., Briggs, A., Berry, C. (2016) Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS) Open Heart, 3, (doi: 10.1136/openhrt-2015-000371)

Layland, J. et al. (2015) Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. European Heart Journal, 36, pp. 100-111. (doi: 10.1093/eurheartj/ehu338)

Layland, J., Rauhalammi, S., Watkins, S., Ahmed, N., McClure, J., Lee, M. M.Y., Carrick, D., O’Donnell, A., Sood, A., Petrie, M. C., Teng Yue May, V., Eteiba, H., Lindsay, M., McEntegart, M., Oldroyd, K. G., Radjenovic, A., Berry, C. (2015) Assessment of fractional flow reserve in patients with recent Non–ST-Segment–Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 8, (doi: 10.1161/circinterventions.114.002207)